IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
13th Nov 2006, 16:15 GMT
Allergy & immunology specialist meets growing demand for outsourced clinical trial testing through a series of strategic hires, capital investments and line of new service offerings
IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division related news:
- IBT Labs will spend $2M to expand division — bizjournals.com Health Care:Pharmaceuticals headlines
- FDA Might Expand Access To Experimental Medications — Health News from Medical News Today
- Big City Diner plans to expand catering, looks for banquet space — bizjournals.com Retailing & Restaurants:Restaurants headlines
- Dr Reddy's Registers to List Shares — Operations-Related News from StratCenter.com
- Genzyme increasing R&D presence in San Antonio area — Radiology News from StratCenter.com
- Akorn, FDC Team Up for Eye Drugs — Pharmaceuticals News from StratCenter.com
- Celesio revenues, profits up — Pharmaceutical Business Review Latest News
- Delta Search Labs spinoff wins Air Force deal for toxin detector — bizjournals.com Health Care:Biotechnology headlines
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection — Pharmaceuticals News from StratCenter.com
- Pharmaceutical Companies Address Barriers to Portfolio Mgmt Success — Pharmaceuticals News from StratCenter.com
Latest news from Bio-Technology News from StratCenter.com:
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout